An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma

Viruses used for gene therapy are usually genetically modified to deliver therapeutic transgenes and prevent viral replication. in contrast, replication-competent viruses may be used for cancer therapy because replication of some viruses within cancer cells can result in their destruction (oncolysis). Viral ribonucleotide reductase expression is defective in the HSV1 mutant hrR3, Cellular ribonucleotide reductase, which is scarce in normal liver and abundant in liver metastases, can substitute for its viral counterpart to allow hrR3 replication in infected cells. Two or three log orders more of hrR3 virions are produced from infection of colon carcinoma cells than from infection of normal hepatocytes in viral replication assays. This viral replication is oncolytic, A single intravascular administration of hrR3 into immune-competent mice bearing diffuse Liver metastases dramatically reduces tumor burden. hrR3-mediated tumor inhibition is equivalent in immune-competent and immune-incompetent mice, suggesting that viral oncolysis and not the host immune response is the primary mechanism of tumor destruction. HSV1-mediated oncolysis of diffuse liver metastases is effective in mice preimmunized against HSV1, These results indicate that replication-competent HSV1 mutants hold significant promise as cancer therapeutic agents.